Endoscopic Resection Brings Excitement to Esophageal Cancer Treatment

Video
Conference|ASCO Annual Meeting: Gastrointestinal Cancer

Cancer Network spoke with Dr. Daniela Molena about the advancements in the treatment of esophageal cancer, including the safety and importance of endoscopic resection for the disease.

Cancer Network spoke with Dr. Daniela Molena about the advancements in the treatment of esophageal cancer, including the safety and importance of endoscopic resection for the disease.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Related Content
High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

High Response Rates Seen with Fruquintinib Combo in HER2– Advanced Gastric/GEJ Cancer

Kyle Doherty
June 4th 2025
Article

Fruquintinib plus chemotherapy and a PD-1 inhibitor elicited an ORR of 80.0% with all partial responses in patients with treatment-naïve gastric/GEJ cancer.

A Sneak Peek at 2025 ASCO From the GU Perspective

A Sneak Peek at 2025 ASCO From the GU Perspective

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
May 15th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

Roman Fabbricatore
June 3rd 2025
Article

The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

Maha H. Hussain, MD;Sarah E. Fenton, MD, PhD
April 8th 2024
Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Disitamab Vedotin/Toripalimab/Trastuzumab Yield Responses in G/GEJ Cancer

Tony Berberabe, MPH
June 2nd 2025
Article

Disitamab vedotin, toripalimab, and trastuzumab demonstrated superior response rates and efficacy in HER2-overexpressing metastatic gastric cancers.

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of prior immunotherapy or tyrosine kinase inhibitor use.

Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC

Roman Fabbricatore
June 2nd 2025
Article

Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.